Research and development of an antimetastatic docetaxel-peptide conjugate (TH1902) against sortilinpositive cancers

The major aim of this research project is to accelerate the development of the SORT1+ oncology platform. This novel platform is based on a new proprietary peptide targeting Sortilin, a key scavenging receptor. Sortilin has been reported to play a role in cell survival and in the progression of human cancers. For instance, Sortilin expression has been associated with the aggressiveness of breast cancers and was observed in other highly metastatic types of cancers such as melanoma and lung cancers. Data that will be generated from this intern will further validate the antimetastatic properties of our docetaxel-peptide conjugate (TH1902) in metastatic cancer animal models and improve the value of SORT1+ technology. The achievement of milestones in this project will create significant value for the partner organization and validate SORT1+ technology as a platform. This will be a key and significant inflexing point for the value of the company that will facilitate the creation of new partnerships and the development of new research projects.

Faculty Supervisor:

Borhane Annabi

Student:

Partner:

Theratechnologies

Discipline:

Life Sciences

Sector:

Manufacturing; Professional, scientific and technical services

University:

Université du Québec à Montréal

Program: